ArticleScientific reports2023
Incidence and risk of pancreatic cancer in patients with chronic pancreatitis: defining the optimal subgroup for surveillance.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Extracellular vesicle biomarkers in pancreatic ductal adenocarcinoma: from bulk detection to single-extracellular vesicle profiling and endoscopic liquid biopsy.Journal of gastroenterology · 2026Review
- Biliary Stent Placement by Endoscopic Retrograde Cholangiopancreatography: Quality Indicators and Technical Applications.Gut and liver · 2026Review
- Appearance of Pancreas Predictive of Cancer Presence: Utility of Computed Tomography Volumetry.Cancers · 2026Article
- Real world evaluation of multiparametric MRI using diffusion weighted imaging and MRCP for pancreatic cancer surveillance.Scientific reports · 2026Observational
- Pancreaticoduodenectomy with longitudinal pancreatojejunostomy for chronic pancreatitis with suspicious pancreatic head mass: our initial experience with open, laparoscopic, and robotic approaches.Surgical endoscopy · 2026Article
- Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer.Journal of gastroenterology · 2026Article
- Acinar-specific loss of activating transcription factor 3 restricts KRASCell death discovery · 2025Article
- Risk of Pancreatic Cancer in Inflammatory Pancreatic Diseases.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2025Review
- Nuclear magnetic resonance-based metabolomics and risk of pancreatic cancer: a prospective analysis in the UK Biobank.Journal of gastroenterology · 2025Article
- Review
- Review
- Incidentally detected pancreatic duct dilatation on ultrasound and role of MRI.Abdominal radiology (New York) · 2025Article
- Article
- New-onset diabetes as an emerging risk group for early detection of pancreatic cancer: current evidence, clinical challenge, and future directions.Frontiers in gastroenterology (Lausanne, Switzerland) · 2025Review
- Inflammation and cancer: molecular mechanisms and clinical consequences.Frontiers in oncology · 2025Review
- Chronic pancreatitis as a driving factor for pancreatic cancer: An epidemiological understanding.World journal of clinical oncology · 2024Article
- The Role of Twist1 in Chronic Pancreatitis-Associated Pancreatic Stellate Cells.The American journal of pathology · 2024Article
- The BRD4 Inhibitor I-BET-762 Reduces HO-1 Expression in Macrophages and the Pancreas of Mice.International journal of molecular sciences · 2024Article
- Pancreatic cancer: from early detection to personalized treatment approaches.Annals of medicine and surgery (2012) · 2024Review
- The Past and Future of Inflammation as a Target to Cancer Prevention.Cancer prevention research (Philadelphia, Pa.) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to present the incidence and risk factors for pancreatic cancer in a multicenter retrospective cohort of patients with chronic pancreatitis (CP). Patients with ICD-10 codes for CP (K86.0, K86.1) who underwent abdominal CT or MRI between January 2010 and December 2021 in seven academic hospitals were analyzed. After exclusions, we identified 727 patients with definite CP with a median follow-up of 3.6 years (range 1.0‒12.9). During 3290 person-years of observation, pancreatic cancers were diagnosed in 16 patients (2.20%, 0.49% per year) after a median follow-up of 2.4 years (range 1.4‒6.6), with an age- and sex-standardized incidence ratio of 18.1 (95% CI 10.4‒29.5). The underlying CPs in the 16 pancreatic cancers were classified as chronic obstructive pancreatitis (10, 63%), chronic obstructive and calcifying pancreatitis (4, 25%), chronic calcifying pancreatitis (1, 6%), and autoimmune pancreatitis (1, 6%). Factors associated with pancreatic cancer development included age (HR 4.830, p = 0.006), parenchymal calcification (HR 0.213, p = 0.003), pancreatic duct stricture (HR 2.706, p = 0.048), and serum CA 19‒9 level (HR 3.567, p = 0.014). After adjustment, age over 60 years (HR 4.540, p = 0.009) and serum CA 19‒9 levels greater than 100 U/mL (HR 3.528, p = 0.015) were independent risk factors for pancreatic cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.